- Home
- RLTY vs RCEL Comparison
RLTY vs RCEL Comparison
Compare RLTY & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLTY
- RCEL
- Stock Information
- Founded
- RLTY 2022
- RCEL N/A
- Country
- RLTY United States
- RCEL United States
- Employees
- RLTY N/A
- RCEL N/A
- Industry
- RLTY Investment Managers
- RCEL Medical/Dental Instruments
- Sector
- RLTY Finance
- RCEL Health Care
- Exchange
- RLTY Nasdaq
- RCEL Nasdaq
- Market Cap
- RLTY 259.2M
- RCEL 308.6M
- IPO Year
- RLTY N/A
- RCEL N/A
- Fundamental
- Price
- RLTY $15.71
- RCEL $9.75
- Analyst Decision
- RLTY
- RCEL Buy
- Analyst Count
- RLTY 0
- RCEL 5
- Target Price
- RLTY N/A
- RCEL $17.25
- AVG Volume (30 Days)
- RLTY 86.7K
- RCEL 191.4K
- Earning Date
- RLTY 01-01-0001
- RCEL 02-13-2025
- Dividend Yield
- RLTY 9.35%
- RCEL N/A
- EPS Growth
- RLTY N/A
- RCEL N/A
- EPS
- RLTY N/A
- RCEL N/A
- Revenue
- RLTY N/A
- RCEL $64,251,000.00
- Revenue This Year
- RLTY N/A
- RCEL $62.11
- Revenue Next Year
- RLTY N/A
- RCEL $31.19
- P/E Ratio
- RLTY N/A
- RCEL N/A
- Revenue Growth
- RLTY N/A
- RCEL 28.14
- 52 Week Low
- RLTY $11.38
- RCEL $7.51
- 52 Week High
- RLTY $14.60
- RCEL $18.93
- Technical
- Relative Strength Index (RSI)
- RLTY 58.43
- RCEL 50.10
- Support Level
- RLTY $15.35
- RCEL $8.37
- Resistance Level
- RLTY $15.67
- RCEL $11.25
- Average True Range (ATR)
- RLTY 0.24
- RCEL 0.55
- MACD
- RLTY -0.01
- RCEL 0.22
- Stochastic Oscillator
- RLTY 81.36
- RCEL 47.92
About RLTY Cohen & Steers Real Estate Opportunities and Income Fund of Beneficial Interest
Cohen & Steers Real Estate Opportunities and Income Fund is an organized, non-diversified, closed-end management investment company. The Fund's primary investment objective is high current income. The Fund's secondary investment objective is capital appreciation.
About RCEL Avita Medical Inc.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the US with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.